ACH-TH vs EC-TH as Neoadjuvant Therapy for HER2-positive EBC
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Breast cancer is the most common malignant tumor in women. EC-TH is one of the standard
chemotherapy regimens for HER-2 positive early breast cancer(EBC). Earlier use of trastuzumab
may improve DFS rate. In this study, the investigators want to find out whether ACH-TH
regimen compared with the EC-TH regimen in HER2+ EBC could improve the pCR rate in
neoadjuvant chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
First Affiliated Hospital, Sun Yat-Sen University Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University